View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Pricing and Market Access
September 1, 2020updated 02 Nov 2021 3:18amPowered by GlobalData

Global healthcare spend to remain stable

Click here to access GlobalData’s Market Access and Pricing Services

Despite projected declines in GDP, driven by self-imposed restrictions on economic activity during lockdowns designed to reduce the spread of COVID-19, healthcare spending will remain stable throughout this year and next, before returning to normal growth levels thereafter. We define healthcare spending as: all public (funded by taxation or mandatory health insurance) plus all private (which includes voluntary health insurance, out of pocket spending, and private other.

Healthcare spending has remained remarkably stable at the global level against the background of declines in other sectors of the economy. Government commitments to maintaining spending growth at a level consistent with pre-pandemic pledges and legislation as well as additional funding spurred by the pandemic will partially offset the recession effects of the hit to GDP, the rise in unemployment and consequent reduction in tax revenue

The additional government healthcare funding needed to combat COVID-19 will partially offset the headwinds emanating from the worsening global macroeconomic environment, netting low, but positive growth in healthcare spending for most of the major economies in 2020.

The pandemic has unleashed broader support by the general public, corporate entities and governments for healthcare system investment, which will drive up public healthcare spending even as public spending in other areas of the economy is deprioritized. Global healthcare spending is forecast to decline 0.1% to USD 8.3 trillion in 2020 before growing 5.8% to USD 8.8 trillion in 2021.

Some highlights from around the globe:

  • The US pharmaceutical market is forecast to grow 2.0% to USD524 billion in 2020 and 7.0% in 2021.
  • For the EU5 markets, health spend is projected to decline 1.6% to USD1.3 trillion in 2020, while pharmaceutical sales are expected to decline 1.6% to USD173 billion in 2020 and to grow 3.4% in 2021.
  • The Japanese pharma market is forecast to gain 1.0% to USD65 billion in 2020 and fall 0.5% in 2021.
  • Pharmaceutical sales in the BRIC-MT markets are projected to decline 2.9% in 2020 to USD280 billion and to grow 11.3% in 2021.

Related Companies

Click here to access GlobalData’s Market Access and Pricing Services

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology